Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Apr;159(8):1623-5.
doi: 10.1111/j.1476-5381.2010.00653.x. Epub 2010 Mar 5.

Activation of submucosal 5-HT(3) receptors elicits a somatostatin-dependent inhibition of ion secretion in rat colon

Affiliations

Activation of submucosal 5-HT(3) receptors elicits a somatostatin-dependent inhibition of ion secretion in rat colon

N Yang et al. Br J Pharmacol. 2010 Apr.

Abstract

Background and purpose: 5-Hydroxytryptamine (5-HT) is a key regulator of the gastrointestinal system and we have shown that submucosal neuronal 5-HT(3) receptors exerted a novel inhibitory effect on colonic ion transport. The aim of the present study was to investigate the precise mechanism(s) underlying this inhibitory effect.

Experimental approach: Mucosa/submucosa or mucosa-only preparations from rat distal colon were mounted in Ussing chambers for measurement of short-circuit current (I(sc)) as an indicator of ion secretion. Somatostatin release was determined with radioimmunoassay. Intracellular cAMP content was measured with enzyme-linked immunoadsorbent assay (elisa). Immunohistochemical techniques were used to study the expression of 5-HT(3) receptors, somatostatin and somatostatin receptors in colonic tissue.

Key results: In rat distal colonic mucosa/submucosa preparations, pretreatment with 5-HT(3) receptor antagonists enhanced 5-HT-induced increases in I(sc). However, in mucosa-only preparations without retained neural elements, pretreatment with 5-HT(3) receptor antagonists inhibited 5-HT-induced DeltaI(sc). Pretreatment with a somatostatin-2 (sst(2)) receptor antagonist in mucosa/submucosa preparations augmented 5-HT-induced DeltaI(sc). Combination of sst(2) and 5-HT(3) receptor antagonists did not cause further enhancement of 5-HT-induced DeltaI(sc). Moreover, both sst(2) and 5-HT(3) receptor antagonists enhanced 5-HT-induced increase in intracellular cAMP concentration in the mucosa/submucosa preparations. 5-HT released somatostatin from rat colonic mucosa/submucosa preparations, an effect prevented by pretreatment with 5-HT(3) receptor antagonists. Immunohistochemical staining demonstrated the presence of 5-HT(3) receptors on submucosal somatostatin neurons and of sst(2) receptors on colonic mucosa.

Conclusion and implications: Activation of neuronal 5-HT(3) receptors in the submucosal plexus of rat colon suppressed 5-HT-induced ion secretion by releasing somatostatin from submucosal neurons.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Effect of 5-HT3 receptor antagonists on 5-HT-induced Isc responses in rat distal colon mucosa/submucosa preparations. (A1) Representative Isc recording with arrow indicating the basolateral application of 5-HT (10 µM) to the mucosa/submucosa preparations pretreated with MDL72222 (0.1 µM). (A2) Summary of the effects of MDL72222 (0.1 µM) on 5-HT-induced ΔIsc. (B1) Representative Isc recording showing the effect of tropanyl-3, 5-dimethylbenzoate (0.1 µM) on 5-HT-induced Isc responses. (B2) Summary of the effects of Tropanyl-3, 5-dimethylbenzoate (0.1 µM) on 5-HT-induced ΔIsc. Values are means ± SEM; **P < 0.01; n= 12. (C1) Effects of different concentrations of MDL72222 on 5-HT-induced Isc responses in rat distal colonic mucosa/submucosa preparations. Numbers in the table indicate the number of tissues demonstrating the variable effect on Isc at different doses of MDL72222. (C2) Summary of the effects of different doses of MDL72222 on 5-HT-induced ΔIsc. Values are means ± SEM; *P < 0.05; **P < 0.01; n= 6 (0.001 µM), n= 12 (0.01 µM), n= 11 (0.1 µM), n= 14 (1.0 µM), n= 12 (10 µM). 5-HT, 5-Hydroxytryptamine; Isc, short-circuit current.
Figure 2
Figure 2
Effects of 5-HT3 receptor antagonist on 5-HT-induced Isc responses in rat colonic mucosa/submucosa and mucosa-only preparations in the presence of TTX. (A1) Representative Isc recording with arrow indicating the basolateral application of 5-HT (10 µM) to the mucosa/submucosa preparations pretreated with MDL72222 (0.1 µM) plus TTX (1 µM). (A2) Summary of the effects of MDL72222 (0.1 µM) plus TTX (1 µM), on 5-HT-induced ΔIsc. Values are means ± SEM; **P < 0.01; n= 9. (B1/C1) Representative Isc recording with arrows indicating the basolateral application of 5-HT (10 µM) to rat mucosa-only preparations pretreated with MDL72222 (0.1 µM, B1) or tropanyl-3, 5-dimethylbenzoate (0.1 µM, C1) plus TTX (1 µM) respectively. (B2/C2) Summary of the effects of MDL72222 (0.1 µM, B2) and tropanyl-3, 5-dimethylbenzoate (0.1 µM, C2) on 5-HT-induced ΔIsc. Values are means ± SEM; *P < 0.05; **P < 0.01; n= 5 respectively. 5-HT, 5-Hydroxytryptamine; Isc, short-circuit current; TTX, tetrodotoxin.
Figure 3
Figure 3
Effect of the sst2 receptor antagonist CYN 154806 on 5-HT-induced Isc responses in rat distal colon mucosa/submucosa preparations. (A1) Representative Isc recording with arrow indicating the basolateral application of 5-HT (10 µM) to the mucosa/submucosa preparations pretreated with CYN 154806 (0.5 µM). (A2) Summary of the effect of CYN 154806 (0.5 µM) on 5-HT-induced ΔIsc. Values are means ± SEM; **P < 0.01; n= 7. (B1) Representative Isc recording with arrow indicating the basolateral application of 5-HT (10 µM) to the mucosa/submucosa preparations pretreated with CYN 154806 (0.5 µM) and MDL72222 (0.1 µM). (B2) Summary of the effect of CYN 154806 (0.5 µM) and MDL72222 (0.1 µM) on 5-HT-induced ΔIsc. Values are means ± SEM; **P < 0.01; n= 4. 5-HT, 5-Hydroxytryptamine; Isc, short-circuit current; sst2, somatostatin receptor-2.
Figure 4
Figure 4
Intracellular cAMP measurement. Summary of the effects of pretreatment with the sst2 receptor antagonist, CYN 154806 (0.5 µM), 5-HT3 receptor antagonists, MDL72222 (0.1 µM) and tropanyl-3, 5-dimethylbenzoate (0.1 µM), and 5-HT4 receptor antagonists, GR113808 (0.5 µM) on 5-HT (10 µM)-stimulated intracellular cAMP production in the rat colonic mucosa/submucosa preparations. **P < 0.01; n= 6 respectively. 5-HT, 5-Hydroxytryptamine; sst2, somatostatin receptor-2.
Figure 5
Figure 5
Expression of 5-HT3 receptor in somatostatin neurons of the rat colonic submucosal plexus. (A–C) Immunoreactivity of 5-HT3 receptor (A) and somatostatin (B) in the frozen sections of the rat distal colon. (D–F) Immunoreactivity of 5-HT3 receptor in whole-mount preparations of the rat distal colon. 5-HT3 receptor (green) was expressed in two neurons of a submucosal ganglion and nerve fibres. Neuronal phenotype was confirmed using a pan-neuronal marker HuC/D (red). (G–I) 5-HT3 receptor (green) and somatostatin (red) was colocalized in neurons in whole-mount preparations of the submucosal plexus. Scale bars, 20 µm. 5-HT, 5-Hydroxytryptamine.
Figure 6
Figure 6
Expression of sst2 receptors in the epithelium of the rat distal colonic mucosa. sst2 receptor immunoreactivity was found to be abundantly expressed in the crypts of the rat distal colonic mucosa (A. lower magnification; B. higher magnification). (C) Omission of the primary antibody of sst2 receptors resulted in no immunostaining. sst2, somatostatin receptor-2.
Figure 7
Figure 7
Radioimmunoassay of somatostatin release in rat colonic mucosa/submucosa preparations. A summary of the effects of pretreatment with different concentrations of 5-HT3 antagonist, MDL72222 (0.1 µM, n= 6) and tropanyl-3, 5-dimethylbenzoate (0.1 µM, n= 5), as well as the sst2 receptor antagonist, CYN 154806 (0.5 µM, n= 5) on the 5-HT (10 µM, n= 6)-stimulated somatostatin release. n= 7. *P < 0.05 compared with 5-HT treatment alone. 5-HT, 5-Hydroxytryptamine; sst2, somatostatin receptor-2.
Figure 8
Figure 8
An illustration of the working model of 5-HT3 and 5-HT4 receptors in rat colonic submucosal plexus and mucosa. (A) Submucosal 5-HT3 receptor-mediated somatostatin-dependent inhibitory neural pathway. Activation of 5-HT3 receptors in the submucosal plexus leads to the release of somatostatin. Somatostatin binds with to the sst2 receptors on the colonic epithelium and reduces the intracellular cAMP concentration, which leads to a decrease of ion secretion in the rat colon. Somatostatin also inhibits secretomotor neuron activity, which leads to a decrease of ion secretion. (B) Epithelial non-neuronal pathway mediated by 5-HT3 and 5-HT4 receptors. In this pathway, 5-HT binds to 5-HT3 and 5-HT4 receptors in the rat colonic epithelium and stimulates ion secretion in rat colon. 5-HT, 5-Hydroxytryptamine; sst2, somatostatin receptor-2.

Similar articles

Cited by

References

    1. Alexander SPH, Mathie A, Peters JA. Guide to Receptors and Channels (GRAC), 4th edn. Br J Pharmacol. 2009;158(Suppl. 1):S1–S254. - PMC - PubMed
    1. Bell D, Zhao Y, McMaster B, McHenry EM, Wang X, Kelso EJ, et al. SRIF receptor subtype expression and involvement in positive and negative contractile effects of somatostatin-14 (SRIF-14) in ventricular cardiomyocytes. Cell Physiol Biochem. 2008;22:653–664. - PubMed
    1. Booth CE, Kirkup AJ, Hicks GA, Humphrey PP, Grundy D. Somatostatin sst(2) receptor-mediated inhibition of mesenteric afferent nerves of the jejunum in the anesthetized rat. Gastroenterology. 2001;121:358–369. - PubMed
    1. Budhoo MR, Kellum JM. Evidence for a 5-HT4 receptor pathway mediating chloride secretion in the rat distal colon. J Surg Res. 1994;57:44–48. - PubMed
    1. Budhoo MR, Harris RP, Kellum JM. 5-Hydroxytryptamine-induced Cl- transport is mediated by 5-HT3 and 5-HT4 receptors in the rat distal colon. Eur J Pharmacol. 1996;298:137–144. - PubMed

Publication types

MeSH terms